Fireside Chat: Is NaV1.8 the Silver Bullet for Pain, or Does Clinical Success Depend on Matching Mechanism to Pain Biology?
9:30 am - Wednesday 27th January 2027
- Is pain better viewed as a collection of biologically distinct diseases?
- Which pain phenotypes are most likely to benefit from NaV1.8 inhibition?
- Where might alternative mechanisms outperform sodium channel blockade?
- Why do promising assets continue to fail despite compelling target biology?
- How should developers match mechanism, indication and patient population to improve clinical success?
